A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers Journal Articles Refereed uri icon

Overview

Published in

  • Investigational New Drugs

Time

Date/time value

  • 2018

Identity

Digital Object Identifier (DOI)

  • 10.1007/s10637-018-0588-7

Additional Document Info

Parent Title

  • INVESTIGATIONAL NEW DRUGS

Volume

  • 36

Issue

  • 5

Publisher

  • Kluwer Academic Publishers